CMRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Chimerix has the Growth Rank of 2.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, Chimerix's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Chimerix's Growth Rank distribution charts can be found below:
* The bar in red indicates where Chimerix's Growth Rank falls into.
Thank you for viewing the detailed overview of Chimerix's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Fred A Middleton | director | 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708 |
David Jakeman | officer: Principal Accounting Officer | C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713 |
Michael A. Sherman | director, officer: Chief Executive Officer | 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
Martha J Demski | director | 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122 |
Robert J. Meyer | director | 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
Michael T. Andriole | officer: Chief Business Officer | C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Cantex Pharmaceuticals, Inc. | 10 percent owner | 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326 |
Victoria Vakiener | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Allen S. Melemed | officer: Chief Medical Officer | C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713 |
Pratik S Multani | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
William Garrett Nichols | officer: Chief Medical Officer | C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494 |
Michael Albert Alrutz | officer: Principal Executive Officer | 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713 |
M Michelle Berrey | officer: Chief Medical Officer | 303A COLLEGE ROAD EAST, PRINCETON NJ 08450 |
Ernest Mario | director | 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928 |
Ed Greissing | director | 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
From GuruFocus
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 04-27-2023
By Marketwired • 09-05-2023
By Marketwired • 08-16-2023
By Value_Insider Value_Insider • 12-08-2022
By sperokesalga sperokesalga • 02-23-2023
By Value_Insider Value_Insider • 10-27-2022
By Stock market mentor Stock market mentor • 01-05-2023
By PurpleRose PurpleRose • 07-13-2022
By GuruFocus Research • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.